Polymorphisms of the cytokine genes TGFB1 and IL10 in a mixed-race population with Crohn’s disease

BMC Research Notes

André Castro Lyra¹  Mauricio Cardeal¹  Denise Carneiro Lemaire¹  Maria Teresita Bendicho¹  Tamara Celi Almeida¹  Genoile Oliveira Santana³  Neogelia Pereira Almeida² 

[1] Federal University of Bahia, Salvador, Brazil;Alameda dos Jasmins, n-220, Apt-1902, Cidade Jardim/Candeal, CEP 40296200, Salvador, Bahia, Brazil;Gastroenterology Unit, Roberto Santos General Hospital, Salvador, Bahia, Brazil

关键词: IL10;    TGFB1;    Polymorphism;    Crohn’s disease;   

Others  :  1141534
DOI  :  10.1186/1756-0500-6-387

 received in 2012-11-04, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Background

Most Crohn’s disease (CD) genes discovered in recent years are associated with biological systems critical to the development of this disease. TGFB1 and IL10 are cytokines with important roles in CD. The aim of this study was to evaluate the association between CD, its clinical features and TGFB1 and IL10 gene polymorphisms.

Methods

This case–control study enrolled 91 patients and 91 controls from the state of Bahia, Brazil. Five single nucleotide polymorphisms (SNPs) were studied in the TGFB1 gene (codon 10 T > C - rs1800470; codon 25 G > C - rs1800471) and IL10 gene (−1082 A > G - rs1800896; -819 T > C - rs1800871; -592 A > C - rs1800872). An analysis of the genetic polymorphisms was performed using a commercial kit. A comparison of allele frequencies and genotypes was estimated by calculating the odds ratio (OR) with a confidence interval adjusted via the Bonferroni test for a local alpha of 1%. A stratified analysis was applied for gender, race and smoking history. Patients with CD were characterized according to the Montreal classification.

Results

The C allele and CC genotype of the TGFB1 gene rs1800470 were both significantly associated with CD. The stratified analysis showed no confounding factors for the co-variables of gender, race and smoking history. The IL10 gene rs1800896 G allele was significantly associated with age at diagnosis of CD, while the T allele of the IL10 gene rs1800871 was significantly associated with perianal disease. The SNPs rs1800871 and rs1800872 were in 100% linkage disequilibrium.

Conclusions

TGFB1 gene polymorphisms may be associated with susceptibility to the development of CD, and IL10 gene polymorphisms appear to influence the CD phenotype in this admixed population.

【 授权许可】

   
2013 Almeida et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
• [2]Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J: Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: Pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take “toll”? World J Gastroenterol 2006, 12:1829-1841.
• [3]Bamias G, Caminelli F: Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007, 23:365-369.
• [4]Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, Palmer CD, Wilde J, Foxwell BM, Gloger IS, Sweeting T, Marsh M, Walker AP, Bloom SL, Segal AW: Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med 2009, 206:1883-1897.
• [5]Sanchez-Munoz F, Domingues-Lopez A, Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008, 14:4280-4288.
• [6]MacDonald TT, Vossenkaemper A, Fantini M, Monteleone G: Reprogramming the immune system in IBD. Dig Dis 2012, 30:392-395.
• [7]Dieckgraefe BK, Stenson WF, Alpers DH: Gastrointestinal epithelial response to injury. Curr Opin Gastroenterol 1996, 12:109-114.
• [8]Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289-298.
• [9]Grutz G: New insights into the molecular mechanism of interleukin 10 mediated immunosupression. J Leukoc Biol 2005, 21:263-265.
• [10]Levings MK, Bacchetta R, Schulz U, Roncarolo MG: The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002, 129:263-276.
• [11]Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, et al.: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010, 42:1118-1125.
• [12]Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
• [13]Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
• [14]Wilke CM, Wang L, Wei S, Kryczek I, Huang E, Kao J, Lin Y, Fang J, Zou W: Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med 2011, 9:217. BioMed Central Full Text
• [15]Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R, Boirivant M: TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn’s disease and ulcerative colitis. Clin Ex Immuno 2003, 134:120-126.
• [16]Correia I, Veny M, Esteller M, Piqué JM, Yagüe J, Panés J, Salas A: Defective IL-10 production in severe phenotypes of Crohn’s disease. J Leukoc Biol 2009, 85:896-903.
• [17]Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L, Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL: Transforming growth factor beta signaling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut 2009, 58:777-789.
• [18]Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP: Cytokine (TNFα, LTα and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000, 1:185-190.
• [19]Wang AH, Lam WJ, Han DY, Ding Y, Hu R, Fraser AG, Ferguson LR, Morgan AR: The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn’s disease susceptibility in a New Zealand population. Hum Immunol 2011, 72:431-435.
• [20]Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ, Sinnott PJ, Hutchinson IV: Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999, 54:386-390.
• [21]Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV: Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 66:1014-1020.
• [22]Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999, 8:93-97.
• [23]Cantor MJ, Nickerson P, Bernstein CN: The role of cytokine gene polymorphism in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol 2005, 100:1134-1142.
• [24]Garcia-Gonzalez MA, Crusius JB, Strunk MH, Bouma G, Pérez–Centeno CM, Pals G, Meuwissen SG, Peña AS: TGFβ1 gene polymorphisms and inflammatory bowel disease. Immunogenetics 2000, 51:869-872.
• [25]Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L, Weir DG, Mahmud N, Smith OP: Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators of Inflamm 2004, 13:181-187.
• [26]Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, Eitner K, Marx M, Rune M, Epplen JT: The IL10 gene is not involved in the predisposition to inflammatory bowel disease. Electrophoresis 2000, 21:3578-3582.
• [27]Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW: IL4, IL10, IL6 and TNF polymorphisms in New Zealand Caucasian Crohn’s disease patients. In J Colorectal Dis 2008, 23:335-337.
• [28]Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez-Arquero M, Garcia-Perez J, Diaz-Rubio M, de la Concha EG: Interleukin −10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis 2005, 11:739-743.
• [29]Mendoza JL, Urcelay E, Lana R, Martinez A, Taxonera C, de la Concha EG, Díaz-Rubio M: Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn’s disease. World J Gastroenterol 2006, 12:443-448.
• [30]Fowler EV, Eri R, Hume G, Johnstone S, Pandeya N, Lincoln D, Templeton D, Radford-Smith GL: TNFα and IL10 SNPs act together to predict disease behaviour in Crohn’s disease. J Med Genet 2005, 42:523-528.
• [31]Bendicho MT, Guedes JC, Silva NN, Santana GO, Dos Santos RR, Lyra AC, Lyra LG, Meyer R, Lemaire DC: Polymorphism of cytokine genes (TGF-beta1, IFN-gamma, IL-6, IL-10, and TNF-alpha) in patients with chronic pancreatitis. Pancreas 2005, 30:333-336.
• [32]Pereira FA, Pinheiro da Silva NN, Rodart IF, Carmo TM, Lemaire DC, Reis MG: Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol 2008, 80:58-64.
• [33]Hume GE, Fowler EV, Lincoln D, Eri R, Templeton D, Florin TH, Cavanaugh JA, Radford-Smith GL: Angiotensinogen and transforming growth factor beta1: novel genes in the pathogenesis of Crohn’s disease. J Med Genet 2006, 43:e51.
• [34]Lennard–Jones JE: Scand J Gastroenterol. 1989, 170:2-6.
• [35]Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Ridell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification on inflammatory bowel disease: Report of a Working Party of 2005 Montreal Congress of Gastroenterology. Can J Gastroenterol 2005, 19:5-36.
• [36]Krieger H, Morton NE, Mi MP, Azevêdo E, Freire-Maia A, Yasuda N: Racial admixture in north-eastern Brazil. Ann Hum Genet 1965, 29:113-125.
• [37]Raymond M, Rousset F: GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 1995, 86:248-249.
• [38]Saito YA, Talley NJ, Andrade M, Petersen GM: Case–control genetic association studies in gastrointestinal disease: review and recommendations. Am J Gastroenterol 2006, 101:1379-1389.
• [39]Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci 2003, 100:177-182.
• [40]Cavalcante LN, Abe-Sandes K, Angelo AL, Machado TM, Lemaire DC, Mendes CM, Pinho JR, Malta F, Lyra LG, Lyra AC: IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Int 2012, 32:476-486.
• [41]Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA, Gershwin ME: Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 2005, 4:450-459.
• [42]Liberek A, Jakóbkiewick-Banecka J, Kloska A, Swiderska J, Kmiec Z, Luczak G, Wierzbicki P, Liberek T, Marek K, Plata-Nazar K, Sikorska-Wisniewska G, Kaminska B, Wegrzyn G: Clinical parameters of inflammatory bowel disease in children do not correlate with four common polymorphisms of the transforminggrowthfactorβ1 gene. Acta Biochim Pol 2011, 58:641-644.
• [43]Burke JP, Mulsow JJ, O’keane C, Docherty NG, Watson RW, O’Connell PR: Fibrogenesis in Crohn’s disease. Am J Gastroenterol 2007, 102:439-448.
• [44]Van Assche G, Geboes K, Rutgeerts P: Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis 2004, 10:55-60.
• [45]Kin TH, Kim BG, Shin HD, Kim JW, Kim CG, KIM JS, Jung HC, Song IS: Tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Korean patients with inflammatory bowel disease. Korean J Gastroenterol 2003, 42:377-386.
• [46]Garza-Gonzalez E, Pérez-Pérez GI, Mendoza-Ibarra SI, Flores-Gutiérrez JP, Bosques-Padilla FJ: Genetic risk factors for inflammatory bowel disease in a North-eastern Mexican population. Inter J Immunogenet 2010, 37:355-359.
• [47]Zhu H, Lei X, Liu Q, Wang Y: Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. Cytokine 2013, 61:146-153.
• [48]Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola RM: The dual role of IL-10. Trends Immunol 2003, 24:36-43.
• [49]Amre DK, Mack DR, Morgans K, Israel D, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Grimard G, Deslandres C, Levy E, Seidman EG: Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn’s disease. Aliment Pharmacol Ther 2009, 29:1025-1031.